Phenolic Profiling and Therapeutic Potential of Certain Isolated Compounds from Parkia roxburghii against AChE Activity as well as GABA A α5, GSK-3β, and p38α MAP-Kinase Genes.
| Autor: | El Gizawy HA; Pharmacognosy Department, Faculty of Pharmacy, October 6 University, 12585 6th of October City, Egypt., Abo-Salem HM; Chemistry and Natural Compounds Department, Pharmaceutical and Drug Industries Research Division, National Research Center, Dokki, 12585 Giza, Egypt., Ali AA; Postgraduate Studies, October 6 University, 12585 Sixth of October City, Egypt., Hussein MA; Biochemistry Department, Faculty of Applied Medical Sciences, October 6 University, 12585 Sixth of October City, Egypt. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ACS omega [ACS Omega] 2021 Jul 26; Vol. 6 (31), pp. 20492-20511. Date of Electronic Publication: 2021 Jul 26 (Print Publication: 2021). |
| DOI: | 10.1021/acsomega.1c02340 |
| Abstrakt: | Parkia roxburghii belongs to the family Mimosaceae; it has been used since ancient times as a cure for different health complications; such as inflammatory and gynecological diseases and hemiplegia. In this investigation, a reversed-phase-high-performance liquid chromatography (RP-HPLC) profile was carried out for P. roxburghii; also, the isolated bioactive compounds including quercetin, catechin, and biochaninA were individually and/or in combination investigated for their inhibitory effects on scopolamine-induced memory impairments in mice, implying that they have the ability to reduce the neurodegenerative effects of scopolamine and thus could be employed as a more effective therapeutic agent in the treatment of Alzheimer's disease (AD) in humans. The possible interactions of Parkia flavonoids with acetylcholinesterase (AChE), γ-aminobutyric acid A receptor, alpha5 (GABA Competing Interests: The authors declare no competing financial interest. (© 2021 The Authors. Published by American Chemical Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|